Details of the Drug

General Information of Drug (ID: DMIYG7Z)

Drug Name
Donepezil
Synonyms Donepezil (transdermal patch, Alzheimer's disease)
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1], [2], [3]
Therapeutic Class
Neurology Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 379.5
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 11.754 mcg/L [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 90% [4]
Clearance
The clearance of drug is 0.13 C 0.19 L/h/kg [6]
Elimination
57% of drug was eliminated in the urine, and 5% was eliminated in the feces [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 70 hours [8]
Metabolism
The drug is metabolized via the CYP3A4 and CYP2D6 in the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3764 micromolar/kg/day [9]
Vd
The volume of distribution (Vd) of drug is 11.8 +/- 1.7 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0029 mg/mL [5]
Chemical Identifiers
Formula
C24H29NO3
IUPAC Name
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
Canonical SMILES
COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
InChI
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
InChIKey
ADEBPBSSDYVVLD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3152
ChEBI ID
CHEBI:53289
CAS Number
120014-06-4
DrugBank ID
DB00843
TTD ID
D0NS6H
VARIDT ID
DR00817
INTEDE ID
DR0530
ACDINA ID
D00211

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Modulator [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acetylcholinesterase (AChE) DTT ACHE 6.39E-02 -1.07 -1.15
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Donepezil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Rivastigmine DMG629M Moderate Additive cholinergic effects by the combination of Donepezil and Rivastigmine. Alzheimer disease [8A20] [48]
Coadministration of a Drug Treating the Disease Different from Donepezil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Additive cholinergic effects by the combination of Donepezil and Bethanechol. Abnormal micturition [MF50] [48]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Donepezil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [48]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Midostaurin. Acute myeloid leukaemia [2A60] [49]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Idarubicin. Acute myeloid leukaemia [2A60] [49]
Arn-509 DMT81LZ Moderate Increased metabolism of Donepezil caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [48]
Gilteritinib DMWQ4MZ Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Gilteritinib. Acute myeloid leukaemia [2A60] [49]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Oliceridine. Acute pain [MG31] [49]
Mepyramine DMB4SFH Moderate Antagonize the effect of Donepezil when combined with Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [50]
Phenyltoloxamine DMKAEQW Moderate Antagonize the effect of Donepezil when combined with Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [50]
Metronidazole DMTIVEN Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Metronidazole. Amoebiasis [1A36] [49]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [49]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Donepezil caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [48]
Posaconazole DMUL5EW Minor Decreased metabolism of Donepezil caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [48]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Terbutaline. Asthma [CA23] [49]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Salbutamol. Asthma [CA23] [51]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Donepezil and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [52]
Desipramine DMT2FDC Moderate Antagonize the effect of Donepezil when combined with Desipramine. Attention deficit hyperactivity disorder [6A05] [53]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Ofloxacin. Bacterial infection [1A00-1C4Z] [49]
Dalfopristin DM4LTKV Minor Decreased metabolism of Donepezil caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [48]
Clarithromycin DM4M1SG Minor Decreased metabolism of Donepezil caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [48]
Sparfloxacin DMB4HCT Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Sparfloxacin. Bacterial infection [1A00-1C4Z] [49]
Gemifloxacin DMHT34O Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Gemifloxacin. Bacterial infection [1A00-1C4Z] [49]
Norfloxacin DMIZ6W2 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Norfloxacin. Bacterial infection [1A00-1C4Z] [49]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Levofloxacin. Bacterial infection [1A00-1C4Z] [49]
Troleandomycin DMUZNIG Minor Decreased metabolism of Donepezil caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [48]
Lomefloxacin DMVRH9C Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Lomefloxacin. Bacterial infection [1A00-1C4Z] [49]
Telithromycin DMZ4P3A Minor Decreased metabolism of Donepezil caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [48]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Retigabine. Behcet disease [4A62] [49]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Donepezil caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [48]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Eribulin. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Minor Decreased metabolism of Donepezil caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Tucatinib DMBESUA Minor Decreased metabolism of Donepezil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Palbociclib DMD7L94 Minor Decreased metabolism of Donepezil caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Bosutinib. Breast cancer [2C60-2C6Y] [49]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [49]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Olodaterol. Chronic obstructive pulmonary disease [CA22] [49]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Halothane. Corneal disease [9A76-9A78] [49]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Sevoflurane. Corneal disease [9A76-9A78] [49]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Probucol. Coronary atherosclerosis [BA80] [49]
Clofazimine DMEBOFW Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Clofazimine. Crohn disease [DD70] [49]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Pasireotide. Cushing syndrome [5A70] [49]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Osilodrostat. Cushing syndrome [5A70] [49]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Donepezil caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [48]
Ivacaftor DMZC1HS Minor Decreased metabolism of Donepezil caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [48]
MK-8228 DMOB58Q Minor Decreased metabolism of Donepezil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [48]
Sertraline DM0FB1J Minor Decreased metabolism of Donepezil caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [48]
Cyclobenzaprine DM1YBRM Moderate Antagonize the effect of Donepezil when combined with Cyclobenzaprine. Depression [6A70-6A7Z] [53]
Nefazodone DM4ZS8M Minor Decreased metabolism of Donepezil caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [48]
OPC-34712 DMHG57U Moderate Antagonize the effect of Donepezil when combined with OPC-34712. Depression [6A70-6A7Z] [53]
Clomipramine DMINRKW Moderate Antagonize the effect of Donepezil when combined with Clomipramine. Depression [6A70-6A7Z] [53]
Doxepin DMPI98T Moderate Antagonize the effect of Donepezil when combined with Doxepin. Depression [6A70-6A7Z] [53]
Maprotiline DMPWB7T Moderate Antagonize the effect of Donepezil when combined with Maprotiline. Depression [6A70-6A7Z] [53]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Donepezil when combined with Mepenzolate. Digestive system disease [DE2Z] [53]
Tetrabenazine DMYWQ0O Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [49]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Deutetrabenazine. Dystonic disorder [8A02] [49]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Ingrezza. Dystonic disorder [8A02] [49]
Cenobamate DMGOVHA Moderate Increased metabolism of Donepezil caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Donepezil caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Phenobarbital DMXZOCG Moderate Increased metabolism of Donepezil caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Donepezil caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Donepezil when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [53]
Tazemetostat DMWP1BH Moderate Increased metabolism of Donepezil caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [48]
Mirabegron DMS1GYT Minor Decreased metabolism of Donepezil caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [48]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Donepezil when combined with Tolterodine. Functional bladder disorder [GC50] [53]
Terbinafine DMI6HUW Minor Decreased metabolism of Donepezil caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Miconazole DMPMYE8 Minor Decreased metabolism of Donepezil caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Ketoconazole DMPZI3Q Minor Decreased metabolism of Donepezil caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Sunitinib. Gastrointestinal stromal tumour [2B5B] [49]
Cyclopentolate DMA8LM5 Moderate Antagonize the effect of Donepezil when combined with Cyclopentolate. General examination [QA00] [54]
Boceprevir DMBSHMF Minor Decreased metabolism of Donepezil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [48]
Telaprevir DMMRV29 Minor Decreased metabolism of Donepezil caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [48]
Isoniazid DM5JVS3 Minor Decreased metabolism of Donepezil caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [48]
Rifapentine DMCHV4I Moderate Increased metabolism of Donepezil caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Fosamprenavir DM4W9B3 Minor Decreased metabolism of Donepezil caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
Fostemsavir DM50ILT Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Cobicistat DM6L4H2 Minor Decreased metabolism of Donepezil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
Etravirine DMGV8QU Moderate Increased metabolism of Donepezil caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [49]
Darunavir DMN3GCH Minor Decreased metabolism of Donepezil caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
BMS-201038 DMQTAGO Minor Decreased metabolism of Donepezil caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [48]
Cinacalcet DMCX0K3 Minor Decreased metabolism of Donepezil caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [48]
Conivaptan DM1V329 Minor Decreased metabolism of Donepezil caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [48]
Givosiran DM5PFIJ Minor Decreased metabolism of Donepezil caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [48]
Belladonna DM2RBWK Moderate Antagonize the effect of Donepezil when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [53]
Berotralstat DMWA2DZ Minor Decreased metabolism of Donepezil caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [48]
Amobarbital DM0GQ8N Moderate Increased metabolism of Donepezil caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [48]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Donepezil when combined with ITI-007. Insomnia [7A00-7A0Z] [53]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Donepezil and Polyethylene glycol. Irritable bowel syndrome [DD91] [57]
Physostigmine DM2N0TO Moderate Additive cholinergic effects by the combination of Donepezil and Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [48]
Glycerol phenylbutyrate DMDGRQO Minor Decreased metabolism of Donepezil caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [48]
Crizotinib DM4F29C Minor Decreased metabolism of Donepezil caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
Ceritinib DMB920Z Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Ceritinib. Lung cancer [2C25] [49]
Dacomitinib DMOH8VY Minor Decreased metabolism of Donepezil caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Osimertinib. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Selpercatinib. Lung cancer [2C25] [49]
Lumefantrine DM29GAD Moderate Decreased metabolism of Donepezil caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [51]
Halofantrine DMOMK1V Minor Decreased metabolism of Donepezil caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [48]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Hydroxychloroquine. Malaria [1F40-1F45] [49]
Primaquine DMWQ16I Minor Decreased metabolism of Donepezil caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [48]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [49]
Idelalisib DM602WT Minor Decreased metabolism of Donepezil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [48]
IPI-145 DMWA24P Minor Decreased metabolism of Donepezil caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [48]
Arsenic trioxide DM61TA4 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Arsenic trioxide. Mature B-cell lymphoma [2A85] [49]
Vemurafenib DM62UG5 Minor Decreased metabolism of Donepezil caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [48]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Donepezil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Danazol DML8KTN Minor Decreased metabolism of Donepezil caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [48]
Exjade DMHPRWG Moderate Increased metabolism of Donepezil caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [48]
Panobinostat DM58WKG Minor Decreased metabolism of Donepezil caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [48]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Thalidomide. Multiple myeloma [2A83] [51]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Donepezil and Siponimod. Multiple sclerosis [8A40] [51]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Donepezil and Fingolimod. Multiple sclerosis [8A40] [58]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Donepezil and Ozanimod. Multiple sclerosis [8A40] [59]
Neostigmine DM6T2J3 Moderate Additive cholinergic effects by the combination of Donepezil and Neostigmine. Myasthenia gravis [8C6Y] [48]
Edrophonium DMCRQHB Moderate Additive cholinergic effects by the combination of Donepezil and Edrophonium. Myasthenia gravis [8C6Y] [48]
Ambenonium DMOP0BL Moderate Additive cholinergic effects by the combination of Donepezil and Ambenonium. Myasthenia gravis [8C6Y] [48]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Romidepsin. Mycosis fungoides [2B01] [49]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Donepezil caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Nilotinib DM7HXWT Minor Decreased metabolism of Donepezil caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Dasatinib DMJV2EK Minor Decreased metabolism of Donepezil caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Phenindamine DMDTC7R Moderate Antagonize the effect of Donepezil when combined with Phenindamine. Nasopharyngitis [CA00] [53]
Dimenhydrinate DM264B3 Moderate Antagonize the effect of Donepezil when combined with Dimenhydrinate. Nausea/vomiting [MD90] [53]
Promethazine DM6I5GR Moderate Antagonize the effect of Donepezil when combined with Promethazine. Nausea/vomiting [MD90] [53]
Rolapitant DM8XP26 Minor Decreased metabolism of Donepezil caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [48]
Cyclizine DM9G7BS Moderate Antagonize the effect of Donepezil when combined with Cyclizine. Nausea/vomiting [MD90] [53]
Granisetron DMIUW25 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Granisetron. Nausea/vomiting [MD90] [49]
Ondansetron DMOTQ1I Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Ondansetron. Nausea/vomiting [MD90] [49]
Bupropion DM5PCS7 Major Decreased metabolism of Donepezil caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [49]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Entrectinib. Non-small cell lung cancer [2C25] [49]
Lorcaserin DMG6OYJ Minor Decreased metabolism of Donepezil caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [48]
Dexfenfluramine DMJ7YDS Minor Decreased metabolism of Donepezil caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [48]
Levomethadyl Acetate DM06HG5 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Levomethadyl Acetate. Opioid use disorder [6C43] [51]
Lofexidine DM1WXA6 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Lofexidine. Opioid use disorder [6C43] [49]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Rucaparib. Ovarian cancer [2C73] [49]
Flavoxate DMKV4NL Moderate Antagonize the effect of Donepezil when combined with Flavoxate. Pain [MG30-MG3Z] [53]
Buprenorphine DMPRI8G Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Buprenorphine. Pain [MG30-MG3Z] [49]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Triclabendazole. Parasitic worm infestation [1F90] [49]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Pimavanserin. Parkinsonism [8A00] [49]
Orphenadrine DMW542E Moderate Antagonize the effect of Donepezil when combined with Orphenadrine. Parkinsonism [8A00] [53]
Abametapir DM2RX0I Moderate Decreased metabolism of Donepezil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [60]
Ranitidine DM0GUSX Moderate Antagonize the effect of Donepezil when combined with Ranitidine. Peptic ulcer [DA61] [53]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Donepezil when combined with Methylscopolamine. Peptic ulcer [DA61] [53]
Famotidine DMRL3AB Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Famotidine. Peptic ulcer [DA61] [49]
Macimorelin DMQYJIR Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Macimorelin. Pituitary gland disorder [5A60-5A61] [49]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Lefamulin. Pneumonia [CA40] [49]
Lonafarnib DMGM2Z6 Minor Decreased metabolism of Donepezil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [48]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Degarelix. Prostate cancer [2C82] [49]
ABIRATERONE DM8V75C Minor Decreased metabolism of Donepezil caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [48]
Enzalutamide DMGL19D Moderate Increased metabolism of Donepezil caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [48]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Relugolix. Prostate cancer [2C82] [49]
Bicalutamide DMZMSPF Minor Decreased metabolism of Donepezil caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [48]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Donepezil when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [53]
Everolimus DM8X2EH Minor Decreased metabolism of Donepezil caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [48]
Gatifloxacin DMSL679 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Gatifloxacin. Respiratory infection [CA07-CA4Z] [49]
Dexamethasone DMMWZET Moderate Increased metabolism of Donepezil caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [48]
Oxamniquine DM2QDX1 Minor Decreased metabolism of Donepezil caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [48]
Quetiapine DM1N62C Moderate Antagonize the effect of Donepezil when combined with Quetiapine. Schizophrenia [6A20] [53]
Mesoridazine DM2ZGAN Moderate Antagonize the effect of Donepezil when combined with Mesoridazine. Schizophrenia [6A20] [53]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Donepezil when combined with Aripiprazole. Schizophrenia [6A20] [53]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Iloperidone. Schizophrenia [6A20] [49]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Paliperidone. Schizophrenia [6A20] [49]
Molindone DMAH70G Moderate Antagonize the effect of Donepezil when combined with Molindone. Schizophrenia [6A20] [53]
Thiothixene DMDINC4 Moderate Antagonize the effect of Donepezil when combined with Thiothixene. Schizophrenia [6A20] [53]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Asenapine. Schizophrenia [6A20] [49]
Pimozide DMW83TP Moderate Antagonize the effect of Donepezil when combined with Pimozide. Schizophrenia [6A20] [53]
Vardenafil DMTBGW8 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Vardenafil. Sexual dysfunction [HA00-HA01] [49]
Voxelotor DMCS6M5 Minor Decreased metabolism of Donepezil caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [48]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Donepezil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [52]
Larotrectinib DM26CQR Minor Decreased metabolism of Donepezil caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
Armodafinil DMGB035 Minor Increased metabolism of Donepezil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [61]
LEE011 DMMX75K Minor Decreased metabolism of Donepezil caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [49]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [49]
Doxorubicin DMVP5YE Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [49]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Pitolisant. Somnolence [MG42] [49]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [49]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Donepezil caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [62]
Cabozantinib DMIYDT4 Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Cabozantinib. Thyroid cancer [2D10] [49]
Elagolix DMB2C0E Moderate Increased metabolism of Donepezil caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [48]
Chlorpheniramine DM5URA2 Moderate Antagonize the effect of Donepezil when combined with Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [53]
Methdilazine DMAUHQX Moderate Antagonize the effect of Donepezil when combined with Methdilazine. Vasomotor/allergic rhinitis [CA08] [53]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Donepezil when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [50]
Acrivastine DMTIGA0 Moderate Antagonize the effect of Donepezil when combined with Acrivastine. Vasomotor/allergic rhinitis [CA08] [53]
Procainamide DMNMXR8 Moderate Antagonize the effect of Donepezil when combined with Procainamide. Ventricular tachyarrhythmia [BC71] [53]
Propafenone DMPIBJK Minor Decreased metabolism of Donepezil caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [48]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Donepezil and Flecainide. Ventricular tachyarrhythmia [BC71] [49]
⏷ Show the Full List of 185 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
FD&C blue no. 2 E00446 2723854 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Monoammonium glycyrrhizate E00352 62074 Emulsifying agent; Flavoring agent
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Zinc sulfate monohydrate E00358 62639 Anticaking agent; Antimicrobial preservative
⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Donepezil 10 mg tablet 10 mg Disintegrating Oral Tablet Oral
Donepezil 5 mg tablet 5 mg Disintegrating Oral Tablet Oral
Donepezil 10 mg tablet 10 mg Disintegrating Tablet Oral
Donepezil 5 mg tablet 5 mg Disintegrating Tablet Oral
Donepezil 23 mg tablet 23 mg Oral Tablet Oral
Donepezil 10 mg tablet 10 mg Oral Tablet Oral
Donepezil 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6599).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001402)
4 Fluoxetine: A case history of its discovery and preclinical development
5 BDDCS applied to over 900 drugs
6 Donepezil FDA label
7 Seltzer B: Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):527-36. doi: 10.1517/17425255.1.3.527 .
8 Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:1-6. doi: 10.1046/j.1365-2125.1998.0460s1001.x.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
11 Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
12 Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
31 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
32 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
35 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
36 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
37 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
38 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
39 Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
40 Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
41 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
42 Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
43 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
44 Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
45 The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
46 Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
47 Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
48 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
49 Canadian Pharmacists Association.
50 Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
51 Cerner Multum, Inc. "Australian Product Information.".
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
54 Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
55 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
56 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
57 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
58 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
60 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
61 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
62 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.